Barr Settles With Sandoz For $22.5M Over Blood Thinner

Law360, New York (June 12, 2006, 12:00 AM EDT) -- Bringing a long-running legal battle to an end, Barr Laboratories Inc. has agreed to a $22.5 million settlement deal with Invamed Inc. and Apothecon Inc. over the raw material source for the blood thinner Warfarin Sodium.

Under the terms of the deal, Barr will fork over a one-time payment of $22.5 million to Invamed and Apothecon, both of which are owned by Sandoz Inc., a unit of Novartis. The payment, totaling approximately 13 cents per share, will be reported in Barr’s results for the quarter ending...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.